Ján Murín, František Mikla, Martin Wawruch, Soňa Kiňová
Type 2 diabetes mellitus is a disease with an increasing incidence, and it also has serious cardiovascular impacts including
high morbidity and mortality. Anti-diabetic drugs, which can long-lastingly improve glycaemia, resulted in reduced
development of diabetic microvascular complications, but has had no influence related to the development of macrovascular
complications, which increase morbidity and mortality of patients.
Only quite recently, we have noticed the advent of 2 new anti-diabetic drug classes (SGLT2 inhibitors and GLP-1 receptor
agonists), which showed an significant cardiovascular benefit in clinical trials. SGLT2 inhibitors are able to influence
the hemodynamic state of a patient and GLP-1 receptor agonists are able to influence atherothombosis in treated patients.
These new anti-diabetic drugs should be therefore used much more often in the treatment of type 2 diabetic patients,
mainly if they also suffer from a cardiovascular disease. This article compares the safety and efficacy of anti-diabetic
drugs, mostly from the cardiovascular perspective of their benefit.